全文获取类型
| 收费全文 | 1488537篇 |
| 免费 | 106877篇 |
| 国内免费 | 2331篇 |
专业分类
| 耳鼻咽喉 | 19945篇 |
| 儿科学 | 47636篇 |
| 妇产科学 | 41028篇 |
| 基础医学 | 220269篇 |
| 口腔科学 | 42836篇 |
| 临床医学 | 132987篇 |
| 内科学 | 299285篇 |
| 皮肤病学 | 34466篇 |
| 神经病学 | 120884篇 |
| 特种医学 | 51992篇 |
| 外国民族医学 | 296篇 |
| 外科学 | 205666篇 |
| 综合类 | 27106篇 |
| 现状与发展 | 3篇 |
| 一般理论 | 630篇 |
| 预防医学 | 128261篇 |
| 眼科学 | 32824篇 |
| 药学 | 109256篇 |
| 6篇 | |
| 中国医学 | 3091篇 |
| 肿瘤学 | 79278篇 |
出版年
| 2021年 | 15012篇 |
| 2019年 | 15252篇 |
| 2018年 | 20728篇 |
| 2017年 | 15007篇 |
| 2016年 | 15872篇 |
| 2015年 | 18133篇 |
| 2014年 | 24789篇 |
| 2013年 | 37307篇 |
| 2012年 | 52532篇 |
| 2011年 | 55627篇 |
| 2010年 | 31547篇 |
| 2009年 | 29176篇 |
| 2008年 | 50150篇 |
| 2007年 | 53491篇 |
| 2006年 | 52285篇 |
| 2005年 | 51333篇 |
| 2004年 | 48777篇 |
| 2003年 | 46389篇 |
| 2002年 | 44629篇 |
| 2001年 | 61781篇 |
| 2000年 | 63131篇 |
| 1999年 | 53211篇 |
| 1998年 | 14877篇 |
| 1997年 | 13383篇 |
| 1996年 | 13631篇 |
| 1995年 | 12770篇 |
| 1994年 | 11856篇 |
| 1992年 | 40607篇 |
| 1991年 | 39894篇 |
| 1990年 | 38554篇 |
| 1989年 | 37074篇 |
| 1988年 | 34385篇 |
| 1987年 | 33670篇 |
| 1986年 | 32121篇 |
| 1985年 | 30219篇 |
| 1984年 | 23040篇 |
| 1983年 | 20090篇 |
| 1982年 | 11946篇 |
| 1979年 | 22037篇 |
| 1978年 | 16153篇 |
| 1977年 | 13395篇 |
| 1976年 | 12475篇 |
| 1975年 | 13577篇 |
| 1974年 | 16535篇 |
| 1973年 | 16309篇 |
| 1972年 | 15346篇 |
| 1971年 | 14358篇 |
| 1970年 | 13628篇 |
| 1969年 | 12875篇 |
| 1968年 | 12013篇 |
排序方式： 共有10000条查询结果，搜索用时 31 毫秒
31.
32.
33.
David Gómez-Almaguer Oscar González-Llano Valentine Jiménez-Antolinez Andrés Gómez-De León 《Expert opinion on pharmacotherapy》2019,20(10):1227-1234
Introduction: The treatment of classical Hodgkin lymphoma (cHL) in children is a story of success. Nowadays, more than 90% of patients are cured and overall survival is nearly 100% at 5 years. Efforts have been made to avoid related effects of therapies; therefore, children are treated using different chemotherapy schemes in comparison with adults.
Areas covered: This review includes a view of the clinical classification and risk assessment in children suffering from HL. The chemotherapy more commonly employed is revisited. The use of PET/CT to evaluate the disease in order to guide therapy is analyzed. New options of chemotherapy and emerging immunotherapy are also included.
Expert opinion: In order to make the right treatment choice, a proper initial assessment of risk is mandatory. The choice of therapy in these kinds of patients must be done according to the experience of the team, and also, the cost and logistics related to the eligible scheme are very important. If possible, efforts must be made to include PET/CT in guiding therapy and avoiding overtreatment and long-term adverse effects in children. New options in immunotherapy are emerging and must be considered with caution in selected patients. 相似文献
34.
Stepanova E. S. Makarenkova L. M. Chistyakov V. V. Rybakov Yu. L. Gukasov V. M. Fedotcheva T. A. Parshin V. A. Votyakov V. A. Shimanovskii N. L. 《Pharmaceutical Chemistry Journal》2019,52(12):1016-1020
Pharmaceutical Chemistry Journal - An HPLC-MS method for simultaneous quantitative determination of a novel gestagenic pharmaceutical and two of its metabolites in rat and rabbit blood sera was... 相似文献
35.
M.F. Werner A. López-Rueda F.X. Zarco J. Blasco L. San Román S. Amaro E. Carrero R. Valero L. Oleaga J.M. Macho N. Bargalló 《Radiologia》2019,61(2):143-152
Purpose
Endovascular treatment with mechanical thrombectomy devices demonstrated high recanalization rates but functional outcome did not correlate with high rates of recanalization obtained. Patient selection prior to the endovascular treatment is very important in the final outcome of the patient. The primary aim of our study was to evaluate the prognostic value of posterior circulation Alberta Stroke Program Early CT Score (pc-ASPECTS) and Pons-Midbrain Index (PMI) scores in patients with Basilar Artery Occlusion (BAO) treated with successful angiographic recanalization after mechanical thrombectomy.Methods
Retrospective single-center study including 18 patients between 2008 and 2013 who had acute basilar artery occlusion managed with endovascular treatment within 24 hours from symptoms onset and with successful angiographic recanalization. The patients were initially classified into two groups according to clinical outcome and mortality at 90 days. For analysis we also divided patients into groups based on pc-ASPECTS (≥8vs.< 8) and PMI (≥3vs.< 3) on non-contrast CT (NCCT) and CT Angiography Source Images (CTASI). Imaging data were correlated to clinical outcome and mortality rate.Results
CTASI pc-ASPECTS, dichotomized at < 8 versus≥8, was associated with a favorable outcome (RR: 2.6; 95% CI: 1.3-5.2) and a reduced risk of death (RR: 6.5: 95% CI: 7.8-23.3). All patients that survived and were functionally independent had pc-ASPECTS score≥8. None of the 5 patients with CTASI pc-ASPECTS score less than 8 survived.Conclusion
PC-ASPECTS on CTASI is helpful for predicting functional outcome after BAO recanalization with endovascular treatment. These results should be validated in a randomized controlled trial in order to decide whether or not to treat a patient with BAO. 相似文献36.
37.
目的 对血清甲状腺球蛋白免疫复合物 (thyroglobulin circulating immune complex, Tg-CIC) 中抗甲状腺球蛋白抗体 (anti-thyroglobulin antibody, Tg-Ab) 含量检测，探讨 Tg-CIC 在甲状腺疾病中的临床以及流行病学意义。方法 收集甲状腺疾病患者血清标本 187 例，每例血清标本分为两组 ( 实验组和空白对照组 )，采用免疫复合物解离专利技术对甲状腺疾病患者血清标本 Tg-CIC 进行分离、解离，通过检测 Tg-CIC 解离后的 Tg-Ab 含量来间接反映甲状腺疾病患者血清中Tg-CIC 水平，按照不同的甲状腺疾病进行分组并对实验结果分析讨论。结果 不同甲状腺患者血清中 Tg-CIC 总阳性率达 92.51%，不同甲状腺疾病血清中 Tg-CIC 的阳性率差异无统计学意义 (χ?=2.917, P>0.05)。不同甲状腺疾病患者间血清游离 Tg-Ab 含量差异无统计学意义 (H=3.882, P>0.05)，不同甲状腺疾病患者间血清 CIC 中 Tg-Ab 含量差异无统计学意义(H=5.5842, P>0.05)。不同甲状腺疾病患者中，甲状腺功能亢进、甲状腺炎以及甲状腺结节患者血清游离 Tg-Ab 的含量与血清 CIC 中的 Tg-Ab 含量呈正相关 (P<0.05)，甲状腺功能减退、甲状腺肿瘤患者血清游离 Tg-Ab 的含量与血清 CIC 中的Tg-Ab 含量不相关 (P>0.05)。结论 在甲状腺疾病患者血清中，大部分可检出 Tg-CIC，与疾病类型无关。而甲状腺疾病患者中，甲状腺功能亢进、甲状腺炎以及甲状腺结节患者血清游离 Tg-Ab 含量与血清 CIC 中 Tg-Ab 含量存在相关性，为我们进一步了解 Tg-CIC 与甲状腺疾病的发生、发展的相关性研究奠定了基础，提供了新的研究视角。 相似文献
38.
39.
Novozhilov A. V. Mindukshev I. V. Korf E. A. Krivchenko A. I. Goncharov N. V. 《Bulletin of experimental biology and medicine》2020,168(4):444-448
Bulletin of Experimental Biology and Medicine - Ammonium, an end-product of catabolism, in low doses can promote adaptation of metabolic pathways in erythrocytes under conditions of extreme... 相似文献
40.
Elizabeth D. Krebs Robert B. Hawkins J. Hunter Mehaffey Clifford E. Fonner Alan M. Speir Mohammed A. Quader Jeffrey B. Rich Leora T. Yarboro Nicholas R. Teman Gorav Ailawadi 《The Journal of thoracic and cardiovascular surgery》2019,157(4):1533-1542.e2